arrow
M

Mieke Van Bockstal

Erasmus MC
H指数:27
被引数:2,868

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Worldwide Survey on Pathological Measurement of Residual Breast Cancer After Neoadjuvant Therapy: Different Interpretations of the ypTNM Classification
2026-01-220
OAAI
Orthogonal validation of anaplastic lymphoma kinase (ALK) immunohistochemistry with molecular analysis for ALK gene rearrangement is required to finetune staining protocols with the D5F3 clone and can impact external quality assessment

需要将间变性淋巴瘤激酶(ALK)免疫组化与ALK基因重排的分子分析进行正交验证,以优化D5F3克隆的染色方案,并且这会影响外部质量评估。

2025-12-080
PRE
Reproducibility of Equivocal HER2 In Situ Hybridization Groups 3 and 4, and Comparison With HER2 mRNA Expression

HER2原位杂交结果为可疑的3组和4组的可重复性及与HER2 mRNA表达的对比

2025-12-010
PRE
Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer

评估短疗程度伐利尤单抗联合高密度EC方案在局部晚期luminal B/HER2(-)或三阴性乳腺癌新辅助治疗中的效果

2025-11-280
OAAI
International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-low and Ultralow Categories

国际专家共识建议:乳腺癌HER2报告,重点关注HER2-low和Ultralow类别

2025-10-280
OAAI
Use of p53 immunohistochemistry can improve diagnostic agreement for differentiated vulvar intraepithelial neoplasia (dVIN): an international reproducibility study

p53免疫组化检测的应用可提高外阴分化型上皮内瘤变(dVIN)的诊断一致性:一项国际可重复性研究

2025-08-050
OAAI
Jacaric Acid Empowers RSL3-Induced Ferroptotic Cell Death in Two- and Three-Dimensional Breast Cancer Cell Models

Jacaric Acid 增强 RSL3 诱导的铁死亡在二维和三维乳腺癌细胞模型中的细胞死亡

2025-04-040
OA
Use of p53 Immunohistochemistry Can Improve Diagnostic Agreement for Differentiated Vulvar Intraepithelial Neoplasia (dVIN): An International Reproducibility Study
2025-03-010
PRE
Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial-mesenchymal transition and tumor-infiltrating lymphocytes

早期乳腺癌对新辅助化疗的反应与上皮间质转化和肿瘤浸润淋巴细胞有关

2025-02-060
OAAI
B-IMMUNE final analysis: a phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers
2023-03-010
PRE
Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study

HER2-Negative乳腺癌免疫组织化学表达水平评估的观察者间差异: 我们能否通过调整标准来改善对低水平HER2表达的识别?国际观察员研究

2023-01-0114
OAAI
Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer
2022-12-0122
OAAI
The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study
2022-03-297
OA
B-immune interim analysis: A phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers
2022-02-150
PRE